Nogapendekin Alfa Inbakicept (N803)

DRUG2 trials

Sponsors

Vadim S Koshkin, ImmunityBio, Inc.

Conditions

Locally Advanced Urothelial CarcinomaMetastatic Urothelial CarcinomaPancreatic CancerPancreatic Cancer ResectableUrothelial CancerUrothelial Carcinoma

Phase 1

N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer

WithdrawnNCT07217496

Vadim S KoshkinLocally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Urothelial Cancer +1

Start: 2026-02-15End: 2027-05-30Updated: 2026-03-17

Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer

Not yet recruitingNCT07488884

ImmunityBio, Inc.Pancreatic Cancer, Pancreatic Cancer Resectable

Start: 2026-03-01End: 2029-06-01Target: 30Updated: 2026-03-23